Using Antibody-Mediated Neutralization of Soluble MIC to Enhance Response to CTLA-4 Blockade

Updated progression-free survival analysis data presented at the 2023 ASCO Annual Meeting favored the combination of nivolumab plus relatlimab in patients with melanoma.

At a median follow-up of 4.1 months, the overall response rate across all patients with advanced solid tumors treated with BL-B01D1 was 45.3%, according to data from a phase 1 study.

While the phase 2 CTEP-P9466 trial met its complete response end point, the trial missed its other co-primary end points in patients with BRAF V600–mutant metastatic melanoma.

In most key prespecified molecularly defined subsets of patients with pretreated KRAS G12C–mutated non–small cell lung cancer, sotorasib continued to demonstrate consistent benefit vs docetaxel.

Epcoritamab plus rituximab/lenalidomide demonstrated antitumor activity in patients with relapsed/refractory follicular lymphoma, including those with high-risk features.

Treatment with lisocabtagene maraleucel elicited encouraging responses and met the primary end point of the TRANSCEND CLL 004 trial in patients with relapsed/refractory CLL/SLL.